🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

With Matt Galsky #EAU24 adjuvant nivolumab in bladder ca: HR 0.76 in ITT & 0.56 in PD-L1 +ve. Clinically meaningful results especially in PD-L1 +ves. No data on PD-L1-ve! OS is not yet significant but this data is impressive. ~60% relapse and 24% get subsequent IO. ~10% ⬆️tox.

#EAU24 Development of the Bladder Utility Symptom Scale (BUSS Utility) Girish Kulkarni UroToday.com 📌n=200 BCa pts, n=200 community 📌10-item questionnaire 📌Final model weighted correlation coefficient between predicted and observed utilities: 0.733 community, 0.734 BCa pts

Development of the bladder utility symptom scale (BUSS Utility): A novel tool to measure utilities and quality of life in #BladderCancer patients. Presented by Girish Kulkarni University of Toronto. #EAU24 written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3U4W4QU European Association of Urology (EAU)

Honoured that our PROGRxN-BCa study was selected as the Best of #EAU24 Abstracts: Urothelial Ca! Girish Kulkarni Univ of Toronto Urology Temerty Centre for AI in Medicine (T-CAIREM) Many thanks to our 🇨🇦 collaborators for making this possible! Wes Kassouf Peter Black Rod Breau & many others not on X! #CUAproud Canadian Urological Association

All eyes & ears at #CBCF24 and Elizabeth Plimack MD for her presentation: Antibody-Drug Conjugates Emerging Data for Efficacy, thank you for your virtual presentation. Wes Kassouf Peter Black Girish Kulkarni Nimira Alimohamed KSridhar

#CBCF24 great day 1 with the participation of leaders in the research and treatment of bladder cancer BladderCancerCanada KSridhar Nimira Alimohamed Lum Lab Maria Jiang Girish Kulkarni Peter Black Wes Kassouf

Spread the word - details finalized for a Sunday, post-dinner gathering at #CUA24 Canadian Urological Association. Band will hit the stage at 930pm. All funds to procureqc Space is limited at the venue so don’t delay. Hope to see you there!

KN057 - papillary only BCGu #bladdercancer cohort. 12 mo DFS =43.5%, median DFS = 7.7 mo, 14% grade 3+ AEs. In ballpark of other drugs (standard caveats apply): 803 = 55% Nado = 44% Atezo = 49% (18 mo) Congrats Andrea Necchi Girish Kulkarni Merck sciencedirect.com/science/articl…

A serious question for adjuvant papillary only trials is what the role.of turbt is vs the therapy. This is why especially for papillary disease the future is neoadjuvant (ie ablative) or randomized.

Final results of #CORE001 trial out now Nature Medicine (1/14) 35 pts with BCG-UR CIS treated w/ Creto + pembro 👉12mo CR (per RBB) = 57.1% (ITT) 👉24mo CR = 54% *(Auth Corr) 👉No patient progressed to MIBC 👉No synergistic toxicity Gary Steinberg nature.com/articles/s4159…

#ride2conquer starting now. Go Team ProActives! Thanks to all for the generous donations. See you at the finish. Riding with Girish Kulkarni. The Princess Margaret Cancer Foundation Univ of Toronto Urology

JUST IN: Durvalumab extends EFS and OS In muscle-invasive bladder cancer —major news with IO moving earlier stages in balder cancer ! OncoAlert Oncology Times Oncology Brothers Tom Powles Targeted Oncology OncLive.com astrazeneca.com/media-centre/p…

This work would not have been possible without the mentorship of Girish Kulkarni Alistair Johnson, and support from CBCIS Univ of Toronto Urology Temerty Centre for AI in Medicine (T-CAIREM) Canadian Urological Association and BladderCancerCanada. Special thanks to all our 🇨🇦 collaborators Wes Kassouf, Peter Black, Rod Breau and many others not on X!

Great podium by Marian S. Wettstein using ICES administrative data to suggest retrograde tumor cell seeding in urothelial CA. Decompression of upper tract ideally with nephrostomy (over stent) in patients with bladder CA. Girish Kulkarni University of Toronto #CUA24

Thank you IBCN Lars Dyrskjøt Kent Mouw for inviting me to talk about #AI in bladder cancer at #IBCN24! Honoured to share the stage with Joseph Liao, MD Andrea Necchi! Enjoyed learning from thought leaders around the 🌎! Proud to represent Univ of Toronto Urology U of T Department of Surgery Temerty Centre for AI in Medicine (T-CAIREM) !

Enjoyed learning about the excellent AI work done by: - Joseph Liao, MD (CystoNet) - Dr. David Berman (AI-enabled tumour grading) - Vignesh Packiam, MD Stephen B. Williams, MD, MBA, MS, FACHE yair lotan Anirudh Joshi Valar Labs (VESTA) ...and many more!

This landed late in my inbox, but fantastic news from ImmunityBio, Inc. regarding their expanded access protocol for BCG! Hoping this moves forward smoothly - a much-needed win for our patients. #BladderCancer #BCGShortage IBCG Bladder Cancer Advocacy Network Dr. Pat Soon-Shiong

PROGRxN-BCa, an #ArtificialIntelligence-based model to predict progression risk in #NMIBC and improve substratification of intermediate-risk disease: an international evaluation of 12659 patients. Presentation by Girish Kulkarni University of Toronto. #EAU25 written coverage by Rashid K. Sayyid USC >

Looking forward to a great ride for a great cause!! @theRide2Conquer Rob Hamilton The Princess Margaret Cancer Foundation